- Bio Protocol Overview
- Asset Role and Supply
- Market Structure
- YearBull Perspective
- Key Risks
- Primary Sources and Review Scope
- Bio Protocol Connects Decentralized Science Communities With Biotech Funding and Liquidity
- Bio Protocol’s role in decentralized science
- How tokenized biotech projects and intellectual property fit the model
- Curation, incentives and liquidity as named mechanisms
- What the BIO token is intended to provide
- The project’s stated background and ecosystem reach
- Historical market context and unresolved operating questions
- Key takeaways
- Risks and unresolved questions
- YearBull Rank update
Bio Protocol Overview
Bio Protocol (BIO) is tracked under bio-protocol. The local profile associates it with BNB Chain Ecosystem, Binance Launchpool, Solana Ecosystem, Ethereum Ecosystem. The source profile maps it to ethereum, base, binance-smart-chain.
Asset Role and Supply
Its role should be evaluated through network or product use, supply design, governance, liquidity, and trading-venue quality. The reviewed record shows circulating supply about 2.15 billion BIO, total supply about 3.32 billion BIO, maximum supply about 3.32 billion BIO. It classifies supply as capped. Supply fields may change through issuance, burns, migrations, or source revisions and should be checked against project records.
Market Structure
At the 2026-09-12 review, the local snapshot placed Bio Protocol at market-cap rank #426, with market capitalization about $54.42 million and reported 24-hour volume of $8.40 million. These values describe observed scale and turnover, not fair value or guaranteed executable liquidity.
YearBull Perspective
The dated snapshot recorded YearBull Rank #947, Bull Score 41/100, Risk Low, and Cycle Early. Rank, Bull, Risk, and Cycle answer different questions and should be read together.
Key Risks
Material risks include market volatility, liquidity deterioration, protocol or governance failure, concentration, and regulatory change. Historical prices, rankings, and classifications do not predict future performance. Verify contract addresses, network support, custody, and venue availability before acting.
Primary Sources and Review Scope
YearBull methodology · Official website · Technical documentation or whitepaper. Profile and market fields were checked against locally stored source records on 2026-09-12. The live snapshot above may be newer than this editorial review.
Bio Protocol Connects Decentralized Science Communities With Biotech Funding and Liquidity
Bio Protocol describes BIO as a curation and liquidity layer for decentralized science, linking patients, scientists and biotech professionals with tokenized projects and intellectual property. Its stated ambition depends on how those communities, assets and networks operate in practice.
Bio Protocol’s role in decentralized science
Bio Protocol is presented as a curation and liquidity protocol for decentralized science, or DeSci. Its stated purpose is to help biotechnology projects attract collective funding, development support and ownership from communities rather than relying only on conventional institutional channels.
The project describes its intended participants as patients, scientists and biotech professionals. In this model, communities can help select or support scientific projects, coordinate resources and participate in tokenized biotech initiatives. public materials does not specify the formal governance process, eligibility rules or decision-making powers available to each participant group.
How tokenized biotech projects and intellectual property fit the model
BIO says it is designed to support the collective funding, construction and ownership of tokenized biotech projects and intellectual property. Tokenization is therefore central to the project’s stated approach: scientific work and related IP are intended to be represented through onchain structures that communities can engage with.
project materials does not establish what legal rights a token represents, how ownership is recorded outside a blockchain, or how scientific revenues, licensing arrangements or research outcomes would be handled. Those details are material to understanding the practical relationship between digital assets and the underlying biotechnology.
Curation, incentives and liquidity as named mechanisms
The protocol identifies three broad components of its proposed scientific economy: decentralized funding, incentives and liquidity. Curation suggests a role in helping communities identify or prioritize scientific projects. Funding is intended to direct capital toward biotech activity, while incentives are described as a way to encourage participation across the network.
Liquidity refers to the ability to create or support markets for the project’s tokenized scientific assets. public materials does not describe the specific contracts, market structures, reward formulas, curation criteria or safeguards used by BIO. As a result, these terms explain the intended functions but not the full operating design.
What the BIO token is intended to provide
BIO is described as the token of the protocol. According to the project’s stated positioning, holding BIO gives users access to a network of scientific communities and intellectual property, with the broader aim of providing exposure to the DeSci economy.
The description does not specify whether token holders receive governance rights, access credentials, fee rights, rewards, voting power or claims on particular assets. It also does not provide supply information, issuance details, allocation data or a complete account of how BIO interacts with project-level tokens. Those distinctions matter because access to a network is not the same as legal ownership of biotech IP or a financial claim on its results.
The project’s stated background and ecosystem reach
Bio Protocol says the team behind it helped create Molecule, described as a platform for tokenizing early-stage biomedicine, and VitaDAO, described by the project as the largest decentralized community for longevity science. These are project statements about background and prior initiatives, not independent findings established by public materials.
The recorded ecosystem categories place BIO across the BNB Chain, Binance Launchpool, Solana, Ethereum, Base and DeSci groupings. Its listed networks are Ethereum, Base, BNB Smart Chain and Solana. public materials does not explain whether the token has identical functionality across these networks, how liquidity is coordinated between them or which deployments support the protocol’s scientific applications.
Historical market context and unresolved operating questions
YearBull’s recorded observations cover 254 entries from December 30, 2025, through September 14, 2026. During that window, BIO’s observed 30-day return was 4.07% and its 90-day return was negative 17.89%. The asset reached a best sequential rank of 1 and a worst sequential rank of 3,438, showing that its relative position varied substantially across the recorded period.
The same observations recorded a dominant Early cycle label and a median absolute daily move of 2.96%. These figures describe market history in the recorded window; they do not establish adoption of Bio Protocol’s scientific products or the success of tokenized research initiatives. The central unresolved questions remain practical: which projects are admitted, what rights attach to their tokens, how scientific and legal risks are handled, and how BIO holders participate in the network.
Key takeaways
- Bio Protocol presents BIO as a curation and liquidity protocol for decentralized science.
- Its stated model seeks to let patients, scientists and biotech professionals collectively fund, build and own tokenized biotech projects and IP.
- The named mechanisms are decentralized funding, participation incentives, project curation and liquidity for tokenized scientific assets.
- BIO is described as a gateway to scientific communities and IP, but project materials does not define specific holder rights or claims.
- The project lists deployments across Ethereum, Base, BNB Smart Chain and Solana, with cross-network operation left unspecified.
Risks and unresolved questions
- The legal rights represented by tokenized biotech projects or intellectual property are not described, including how onchain records relate to offchain ownership and licensing.
- The protocol’s curation criteria, governance structure, funding process, incentive design and liquidity mechanisms are unspecified.
- The relationship between BIO and any project-level scientific tokens is not established, including whether BIO provides governance, access, rewards or economic claims.
- Cross-network functionality is unclear: public materials does not identify which deployments support particular features or how liquidity moves between networks.
- Biotechnology projects carry scientific, regulatory, development and commercialization uncertainties that are not addressed in project materials.
YearBull Rank update
Latest available YearBull Rank for bio-protocol: #1307.
Rank movement (time windows).
Reading rule: lower is better in this ranking.
- 7d window (2026-10-17): #1165 → #1307 (down by 142).
- 30d window (2026-09-24): #256 → #1307 (down by 1051).
YearBull Rank is a comparative ordering used on YearBull to place a coin versus others using a consistent set of inputs. Lower rank numbers correspond to stronger relative placement.
Risk framing: a calm line with small steps can be healthier than spikes. If the curve whipsaws, treat the rank as fragile.
Liquidity read: a steadier line can indicate steadier access. If the line reacts in bursts, watch for calendar-driven liquidity.
Cycle placement: sideways periods still reshuffle relative placement. If 7d and 30d disagree, treat it as a transition window.
Access context: fragmentation can make rank more reactive. If the line range widens, access or routing may be changing.
